The long-term outcomes of patients with hepatocellular carcinoma after living donor liver transplantation: a comparison of right and left lobe grafts
- 14 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Surgery Today
- Vol. 42 (6), 559-564
- https://doi.org/10.1007/s00595-011-0086-4
Abstract
The feasibility of living donor liver transplantation (LDLT) using left lobe (LL) grafts has been demonstrated. However, the long-term outcome of the hepatocellular carcinoma (HCC) patients with LL grafts has not been elucidated. The aim of this study was to analyze the long-term outcomes after LDLT for HCC according to the graft type. A retrospective analysis was performed evaluating the outcomes of LL graft recipients (n = 82) versus recipients of RL grafts (n = 46). The analysis endpoints were the overall and recurrence-free survival after LDLT. The demographics of both recipients and donors, and the tumor characteristics associated with the graft type were also analyzed. The graft volume (436 ± 74 g), as well as the graft volume-standard liver volume rate (38.3 ± 6.2%) of the LL graft group were significantly decreased as compared to those of the RL graft group (569 ± 82 g, 46.3 ± 6.7%; p < 0.01). The 1-, 3-, 5- and 7-year overall survival rates of the LL graft group were 88.2, 80.2, 75.7 and 72.4%, respectively, which were not significantly different compared to those of the RL graft group (95.4, 87.3, 87.3 and 87.3%). The recurrence-free survival rates of the LL graft group (89.1% at 1 year, 78.8% at 3 years, 75.8% at 5 years and 70.3% at 7 years) were similar to those of the RL graft group (88.6, 88.6, 88.6 and 88.6%). The mean peak postoperative total bilirubin levels and duration of hospital stay after surgery for the LL grafting donors were significantly decreased as compared to those of the RL grafting donors (p < 0.01). The rate of severe complications (over Clavien’s IIIa) associated with LL graft procurement was 6.2%, which was lower than that in the RL graft group (15.6%). The long-term outcomes in the HCC patients with LL grafts were similar to those of patients receiving RL grafts, and the outcomes of the donors of LL grafts were more favorable. Therefore, LL grafts should be considered when selecting LDLT for HCC to ensure donor safety.Keywords
This publication has 19 references indexed in Scilit:
- Growth of hepatocellular carcinoma in the regenerating liverLiver Transplantation, 2011
- Living Donor Hepatectomies with Procedures to Prevent Biliary ComplicationsJournal of the American College of Surgeons, 2010
- Impact of Des-Gamma-Carboxy Prothrombin and Tumor Size on the Recurrence of Hepatocellular Carcinoma After Living Donor Liver TransplantationTransplantation, 2009
- Donor Risk in Adult-to-Adult Living Donor Liver Transplantation: Impact of Left Lobe GraftTransplantation, 2009
- Liver transplantation for hepatocellular carcinomaJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- Impact of a Left-Lobe Graft Without Modulation of Portal Flow in Adult-to-Adult Living Donor Liver TransplantationAmerican Journal of Transplantation, 2008
- Living Donor Liver Transplantation for Hepatocellular Carcinoma: Tokyo University SeriesDigestive Diseases, 2007
- Hepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver TransplantationAmerican Journal of Transplantation, 2007
- Documented deaths of hepatic lobe donors for living donor liver transplantationLiver Transplantation, 2006
- Validity of preoperative volumetric analysis of congestion volume in living donor liver transplantation using three-dimensional computed tomographyLiver Transplantation, 2005